Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(290)
•••
Post by WALAkangUYABon Feb 04, 2021 1:14pm
76 Views
Post# 32471595

LEGALIZATIONS OF GREEN-LEAF

LEGALIZATIONS OF GREEN-LEAF
Sponsored Post:
According to Pew Research Center survey found that approx. 67% of the US supports legalization. Would you like to explore some of the Legalization of these Plant Based Product?
 
And It was said that moving likelihood of even more legalization throughout the U.S., fueled by Joe heading to the White House and more recently a Democratic senate, could mean related stocks have the potential for higher highs.
 
It is said that Gallup survey found that 66% of Americans are in favor of legalization. That’s up from just 60% in 2016. On top of that, 14% of Americans now use Plant based products.check disclaimer on profile and landing page.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities